Tildrakizumab pre-filled syringe
- Drugs List
- Therapeutic Indications
- Precautions and Warnings
- Pregnancy and Lactation
- Side Effects
Pre-filled syringe containing tildrakizumab.
Moderate to severe plaque psoriasis
Treatment of adults with moderate to severe plaque psoriasis who are candidates for systemic therapy.
100mg at weeks 0, 4, and every 12 weeks thereafter.
Higher dose (may be required by certain patients, such as those with a higher disease burden or a body weight above 90kg)
200mg at weeks 0, 4, and every 12 weeks thereafter.
Additional Dosage Information
Consider discontinuing treatment in patients that do not respond after 28 weeks of treatment. Some patients with initial partial response may subsequently improve with continued treatment beyond 28 weeks.
Administered via subcutaneous injection. Alternate injection sites, and do not inject into tender, bruised, red, hard, thick or scaly areas of skin, or areas affected by plaque psoriasis.
Children under 18 years
Within 4 weeks of live viral or bacterial vaccination
Precautions and Warnings
History of recurrent infection
History of tuberculosis
Avoid live vaccines during and for 17 weeks after treatment
Administration of live vaccines should occur 4 weeks before initiation
Before starting therapy ensure immunisations are up to date
Consider prophylactic anti-tuberculosis therapy if appropriate
Treat and control infections prior to commencing therapy
Record name and batch number of administered product
Rotate injection site each day when injecting the same region
Treatment to be administered by or under supervision of specialist
Advise patient to report symptoms of infection immediately
Advise patient to seek med advice if signs/symptoms of tuberculosis develop
Consider stopping treatment if severe uncontrolled infections occur
Oversuppression of immune system may increase susceptibility to infection
Discontinue if hypersensitivity reactions occur
Female: Contraception required during and for 17 weeks after treatment
Each pre-filled syringe is for single use only.
Pregnancy and Lactation
Tildrakizumab is contraindicated during pregnancy.
There is limited data on the use of tildrakizumab during pregnancy. Though there is no evidence of reproductive toxicity in animal studies, the manufacturer contraindicates the use of tildrakizumab during pregnancy as a precautionary measure.
Tildrakizumab is contraindicated during breastfeeding.
There is limited data on the use of tildrakizumab in breastfeeding. The manufacturer contraindicates the use of tildrakizumab in breastfeeding, stating that it is unknown whether the drug is excreted in breast milk, and a risk to the nursing infant cannot be excluded. Animal studies suggest that negligible amounts of the drug may be excreted in breast milk.
LactMed suggests that the high molecular weight of tildrakizumab may limit the amount of the drug absorbed by the breastfed infant, and that it may be destroyed in the infant's gastrointestinal tract.
Pain / soreness (injection site)
Upper respiratory tract infection
It is strongly recommended that the UK National Poisons Information Service be consulted on cases of suspected or actual overdose where there is doubt over the degree of risk or about appropriate management.
The following number will direct the caller to the relevant local centre (0844) 892 0111
Information may be obtained if you have access to ToxBase the primary clinical toxicology database of the National Poisons Information Service. This is available via password on the internet ( www.toxbase.org ) or if this is unavailable at the backup site ( www.toxbasebackup.org ).
Last Full Review Date: January 2020
Summary of Product Characteristics: Ilumetri 100mg solution for injection in pre-filled syringe. Almirall Limited. Revised January 2020.
US National Library of Medicine. Toxicology Data Network. Drugs and Lactation Database (LactMed).
Available at: https://toxnet.nlm.nih.gov/cgi-bin/sis/htmlgen?LACT
Tildrakizumab Last revised: 3 December 2018
Last accessed: 06 January 2020
Already a member? Log in
Medscape UK | Univadis prescription drug monographs & interactions are based on FDB Multilex Content
FDB Disclaimer : FDB Multilex is intended for the use of healthcare professionals and is provided on the basis that the healthcare professionals will retain FULL and SOLE responsibility for deciding what treatment to prescribe or dispense for any particular patient or circumstance.